HIV pipeline 2019: new drugs in development

Introduction

Recently approved new HIV drugs
- doravirine
- doravirine/TDF/3TC - FDC
- dolutegravir/3TC - dual FDC
- ibalizumab (Trogarzo) - mAb

Submitted applications or completed phase 3
- cabotegravir (oral and LA)
- cabotegravir-LA/rilpivirine-LA FDC
- fostemsavir - attachment inhibitor

Compounds in phase 3 development
- leronlimab - mAb
- UB-421 - mAb

Compounds in phase 1/2 studies
- MK-8591 (EFdA) - NRTI; MK-8591/doravirine - FDC
- GS-9131 - NRTI
- VRC01, VRC01LS and VRC07-523LS - bNAbs
- Other bNAbs: 3BNC117, 10-1074, PGDM1400, PGT121

elsulfavirine - NNRTI
ABX464 - Rev inhibitor
GSK3640254 - maturation inhibitor

Preclinical compounds of interest
- combinect (GSK3732394) - adnectin/fusion inhibitor
- GS-P11 - protease inhibitor
- GS-CA1 - capsid inhibitor
- MK-8583, MK-8527, MK-8558

Conclusion

References

i-Base publications

Figures and tables
- Figure 1: HIV pipeline 2019: targets in the HIV lifecycle
- Table 1: Recently approved and submitted drugs
- Table 2: Likely positioning for new drugs
- Table 3: HIV pipeline compounds by development phase
- Table 4: Compounds with long-acting formulations
HIV pipeline 2019: new drugs in development

Simon Collins, HIV i-Base
This is the third year that i-Base has produced the HIV pipeline review as part of our Fit for Purpose report on antiretroviral treatment optimisation.

Two versions are available:
1. This version include more information each drug, with full references.
2. The “Pipeline-lite” version has a summary for each drug and is included in the i-Base Fit For Purpose report.

Both electronic versions (web and PDF) include hyperlinks to all research sources and references.

This review is based on HTB reports over the last year and coverage from CROI, IAS, EACS, Glasgow and other conferences. It also refers to some studies that will be presented at the AIDS 2019 conference being held in Mexico City from 21–24 July 2019.

http://www.i-Base.info/hiv-pipeline-report-2019

Introduction

Over the last year there were three new approvals of new drugs or fixed dose combinations (FDCs).

These included the new NNRTI doravirine (also in an FDC) and the dual FDC of dolutegravir/lamivudine. Also, although ibalizumab was approved in the US in March 2018 as the first monoclonal antibody, with an indication to treat multiple drug resistant HIV, approval in the EU is still pending as we went to press. (Table 1)

The FDA decision on the first injectable ART is imminent with approval expected based on impressive results from phase 3 studies.

And intriguing results from some broadly neutralising monoclonal antibodies (bNAbs) - notably those with long-acting formulations - show the potential to maintain viral suppression after ART has been stopped.

As with long-acting ARVs, these long-acting bNAbs also have important potential as PrEP.

The most quickly progressing compound is MK-8591, an NRTI with extremely high potency, in development both as treatment and PrEP and with a slow-release implant formulation that allows once-a-year administration.

Figure 1 updates the HIV pipeline by target and Tables 2 and 3 summarise compounds by development stage and likely use.

Finally, Table 4 highlights long-acting compounds. Over the next 5-10 years ART might become much simpler than taking a single pill once a day - with some compounds showing the potential for weekly, monthly, and perhaps even annual dosing.

Table 2: Likely positioning for new drugs

<table>
<thead>
<tr>
<th>Indication</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment-naive</td>
<td>DTG/3TC; doravirine/3TC/TDF, MK-8591, GS-</td>
</tr>
<tr>
<td></td>
<td>9131, ABX-464</td>
</tr>
<tr>
<td>Switch option on ART</td>
<td>DTG/3TC; doravirine/3TC/TDF, MK-8591 etc.</td>
</tr>
<tr>
<td>Multidrug resistance (MDR)</td>
<td>ibalizumab, fostemsavir, MK-8591, GS-</td>
</tr>
<tr>
<td></td>
<td>9131; ABX-464; all mAbs, likely other new</td>
</tr>
<tr>
<td></td>
<td>compounds</td>
</tr>
<tr>
<td>PrEP</td>
<td>CAB-LA, MK-8591; VRC01, other bNAbs,</td>
</tr>
<tr>
<td>Maintenance without ART</td>
<td>bNAbs - in combinations as switch after</td>
</tr>
<tr>
<td></td>
<td>viral load suppressed on ART.</td>
</tr>
</tbody>
</table>
Currently approved new HIV drugs

Over the last year, three new drugs or FDCs were approved. See Table 1.

Although the PI-based FDC of darunavir/cobicistat/FTC/TAF (Symtuza) was approved in the US in July 2018, this had been approved in the EU six months earlier and was reported last year in the 2018 pipeline report.

Doravirine (Pifeltro) and doravirine/TDF/3TC (Delstrigo)
The NNRTI doravirine (Pifeltro) was also approved in the US (August 2018) and the EU (November 2018) together with an FDC (Delstrigo) combined with generic tenofovir DF (TDF) and generic lamivudine (3TC). [4, 5]

Doravirine is a once-daily NNRTI from Merck that can be taken with or without food. It has few drug interactions and retains activity against common first generation NNRTI mutations (K103N, Y181C, G190A and E138K).

Although current guidelines have moved to preferring integrase inhibitor-based first line treatment, NNRTIs are likely to still be used before protease inhibitors as alternatives. Doravirine has a better tolerability profile compared to efavirenz (which is still widely-used despite the guidelines), but use might depend on being a less expensive option (including to integrase inhibitors).

Doravirine is being studied as part of a three-drug combination 3TC plus the investigational NRTI MK-8591. It is also being studied in dual combination with MK-8591.

Results from both these studies are due to be presented at IAS 2019 in two late-breaker presentations. [6, 7]
Dolutegravir/lamivudine (Dovato)

A dual combination of the integrase inhibitor dolutegravir with a single NRTI lamivudine was approved in the US in April 2019 and in Europe in July 2019. [8, 9]

This was based on phase 3 studies presented at AIDS 2018. [10]

The GEMINI studies showed that dual therapy with DTG/3TC was non-inferior to triple ART.

The disadvantages of dual therapy (for example, when HBV is a concern) are currently likely to outweigh advantages in low- and middle-income settings.

However, in high-income settings, with easier access to monitoring, the use for DTG/3TC is likely to be very different, especially if priced lower than other three-drug FDCs. The results are also encouraging for people who cannot use many other NRTIs.

A sub-study from the phase 3 ASPIRE study showed no differences in low levels viraemia <50 copies/mL in 2-drug vs 3-drug arms. [11]

GEMINI 96-week results are due to be presented at IAS 2019 together with another analysis of viral dynamics at low levels. [12, 13]

Ibalizumab (Trogarzo) - mAb - EU only

Ibalizumab was approved by the US FDA in March 2018. Although given a positive opinion in the EU in April 2019, it is currently still awaiting a final decision in the EU. [14, 15]

Ibalizumab as the first monoclonal antibody to treat HIV positive people with multidrug resistance who are currently on failing ART.

Ibalizumab was developed by TaiMed Biologics. It is marketed in the US and Canada with the trade name Trogarzo by Theratechnologies. The US list price for ibalizumab is US $ 118,000 (WAC/Wholesale Acquisition Cost), which does not include costs for providing the infusions (the product is not self-administered). Easier to use formulations are also being studied.

Although this development took many years – with Phase 1b efficacy results first reported in 2008 – it is a considerable achievement for any compound to be the first drug approved in a new class.

Table 1: Recently approved and submitted HIV drugs

<table>
<thead>
<tr>
<th>Compound &amp; company</th>
<th>Class</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Approved</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>doravirine and doravirine/ TDF/3TC Merck/MSD</td>
<td>NNRTI and NRTI FDC</td>
<td>Active against first generation NNRTI resistance. Non-inferior to efavirenz. FDC using doravirine with two generic NRTIs. Approved in US in August 2018 and EU in November 2018.</td>
</tr>
<tr>
<td>dolutegravir/3TC ViiV Healthcare</td>
<td>INSTI and NRTI FDC</td>
<td>Phase 3 GEMINI studies as initial ART are complete. Week-96 results expected at IAS 2019. Approved in the US in April 2019 and in the EU in July 2019.</td>
</tr>
<tr>
<td>ibalizumab (Trogarzo) Theratechnologies</td>
<td>mAb</td>
<td>Approved by FDA in the US in March 2018 and given positive opinion in the EU in April 2019. Still awaiting EU final decision. Indication for multiple drug resistant HIV.</td>
</tr>
<tr>
<td><strong>Submitted applications or completed phase 3</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cabotegravir/rilpivirine long-acting (LA) injections ViiV Healthcare</td>
<td>INSTI and NNRTI long acting FDC injections</td>
<td>Submitted to FDA in April 2019 based on results from phase 3 studies.</td>
</tr>
<tr>
<td>fostemsavir (GSK3684934) ViiV Healthcare</td>
<td>ap120 attachment inhibitor</td>
<td>Phase 3 BRIGHTe study completed with 24-week results in treatment-experienced with extensive drug resistance. Regulatory application not yet submitted.</td>
</tr>
</tbody>
</table>

Cabotegravir/rilpivirine long-acting (LA) injections

On 29 April 2019, ViiV Healthcare announced that the long-acting two-drug injection formulation of cabotegravir/ rilpivirine had been submitted to the US FDA. [16]

Submission was based on 48-week results from the phase 3 FLAIR and ATLAS studies that were presented at CROI 2019. [17]

These studies reported >90% viral suppression to <50 copies/mL at week-48 meeting criteria for non-inferiority compared to three-drug oral therapy.

Cabotegravir (CAB) is a second-generation integrase inhibitor being developed as both an oral tablet and long-acting (CAB-LA) injectable formulation.
The oral formulation is primarily to use before using CAB-LA injections. CAB-LA is being studied both as treatment (coformulated with rilpivirine LA) and as single-dose for use as PrEP.

Both CAB formulations are being developed by Viiv Healthcare with the FDC in collaboration with Janssens.

CAB-LA has an extremely long half-life: a single injection resulted in drug levels that were still detectable in some people after more than a year. This requires an essential oral dosing lead-in phase before using the injection to screen for risk of a hypersensitivity reaction. The long half-life means that anyone stopping CAB-LA when used as treatment needs to switch to alternative ART (rather than interrupting treatment). When used as PrEP, current studies recommend switching to daily oral PrEP for a year.

However, a presentation at the HIVR4P conference in October 2018 reported cases where therapeutic levels of cabotegravir could still be detected after 2.5 years in men and 3.5 years in women. [18]

The oral formulation has a similar drug resistance profile to dolutegravir.

Pooled results from the FLAIR and ATLAS studies will be presented at IAS 2019, including presentations about participant quality of life using injections. [19, 20, 21]

Results will also be presented for a sustained release long acting cabotegravir implant to be used for PrEP. [22]

**Fostemsavir - attachment inhibitor**

Fostemsavir (GSK3684934) is an attachment inhibitor that binds to gp120 and prevents conformational changes needed for attachment.

It is active against nearly all HIV-1 subtypes, though not sub-type AE or group O and has no in vitro cross resistance to drugs from other classes.

Updated 48-week results were presented at Glasgow 2018 from the phase 3 BRIGHTe study. [23]

This was an advanced patient group with CD4 count at screening less than 200 cells/mm³ in 72% and 50 cells/mm³ in 41% of the group. Previous use of integrase inhibitors and protease inhibitors were reported for 80% and 96%, respectively.

At week 48, by snapshot analysis, 54% participants in the randomised study (146/272) and 38% (38/99) in the open label study had viral load <40 copies/mL. These were similar to rates at week 24.

Two posters were also presented at CROI 2019 supporting activity in treatment-experienced participants. [24, 25]

Currently, the submission is still being prepared for regulatory agencies, the timeline might be related to Viiv issues linked to scaling up manufacturing capacity.

Two presentations at IAS 2019 will present 96-week results from the BRIGHTe study. [26, 27]

This compound is being developed by Viiv Healthcare.

Compounds in phase 3 development

Two bNAbs are in phase 3 development although there have been little new data on both these compounds over the last year.

**Leronlimab - mAb**

Leronlimab (previously PRO 140) is a humanised IgG4 monoclonal antibody that blocks HIV entry by binding to CCR5 but is active against maraviroc-resistant virus.

Leronlimab has been in development for more than a decade, but that has been designated fast-track status, for potential to treat MDR HIV. In addition to use as an ARV in combinations leronlimab is also being studied as a switch treatment after viral suppression on oral ART. Some people have reported sustained viral suppression for two years using weekly subcutaneous injections.

Preliminary results from a phase 2 study using this strategy were presented at CROI 2019. [28]

Unfortunately, this reported a high failure rate at the initial 350 mg dose that was not overcome with higher doses. Approximately 65% (149/226) of participants in the 350 mg, 33% (38/115) in the 525 mg arm and 14% (6/14) in the 700 mg arm, had confirmed viral rebound >200 copies/mL. Failure rates might increase further as some participants are still ongoing. Some of these participants are counted more than once as people with viral failure were given the option to return to ART or roll over to a higher dose of leronlimab. Resistance results from this use of monotherapy have not yet been presented.

Leronlimab is also being studied in non-HIV setting as prophylaxis against graft vs host disease (GVHD) in people undergoing allogeneic stem cell transplant. [29]

Leronlimab is being developed by CytoDyn.

No further results are expected at IAS 2019.

**UB-421 - mAb**

UB-421 is a broadly neutralising mAb that targets CD4 binding with in vitro data that suggest comparable or greater potency compared to other compounds, including VRC01 and 3BNC117. No new clinical data has been presented since 2017.

It is being developed by the Taiwanese company United BioPharma, with research sites in Taiwan. Although two phase 3 studies are listed to start in 2020, they were previously both due to start in 2018. Neither study is currently open to recruitment.

One is a randomised (1:2) open-label study in 375 participants on stable ART who will continue on current treatment or switch to monotherapy with UB-421. [30]

The second will add UB-421 or placebo to currently failing ART in 20 treatment experienced participants with drug resistance, followed by optimised background ART and open label UB-421 to all participants out to 435 weeks. [31]
The most recent data were presented at CROI 2017 but published in April 2019 in the NEJM. This was a phase 2 study in 29 virally suppressed participants on ART who used UB-421 monotherapy during an 8-week treatment interruption. UB-421 was given by infusion either 10 mg/kg weekly or 25 mg/kg every two-weeks. [32]

Although there were no cases of viral rebound during the monotherapy phase, viral load rebounded at 35 to 62 days after the last UB-421 dose in five participants who delayed restarting ART. All five later restarted ART and viral load became undetectable. No further results are expected at IAS 2019.

Compounds in phase 1/2 studies

The compounds in this section include some that are likely to advance quickly into phase 3 studies and some where there has been little progress over the last year.

MK-8591 (EFdA) - NRTI

MK-8591 is a very interesting NRTI in development by Merck that is notable for high potency (currently using a 0.25 to 2.25 mg oral daily dose), a long plasma half-life that allows once-weekly oral dosing, a slow-release removable implant that might only require annual dosing and ongoing studies looking at use for both treatment and PrEP.

A single dose of MK-8591 (30 mg, 10 mg, 2 mg, 1 mg or 0.5 mg) in 30 treatment-naive participants (n=6 for each arm), produced mean viral load reductions at day 7 that were dose-related and ranged from approximately –1.2 logs (for the 0.5 mg, 1.0 mg and 2.0 mg groups) to approximately –1.6 logs (for the 10 mg and 30 mg group).

The latest results relating to potency and activity against drug resistance virus were presented in a poster at CROI 2019. [33]

This showed 4-fold lower IC50 for MK-8591 triphosphate than any other marketed NRTI with potential to use doses of 0.25 mg daily or 10 mg weekly. Common NRTI mutations, including M184I/V, K65R, and K70E, only confer low fold-shifts in antiviral potency and MK-8591 has greater inhibitory quotients against these drug-resistant mutations than those of TDF, TAF, and 3TC with WT HIV.

The potential for PrEP was shown using weekly oral doses of MK-8591 or placebo for three months in 16 macaques who were then exposed to rectal SIV (on day 6 of every weekly cycle) for 12 weeks, protecting all animals in the active arm. [34]

Preliminary results also suggested that a slow release implant might provide protection as PrEP for more than one year.

MK-8591 is also included in an FDC with 3TC and doravirine and is also being studied as dual therapy with doravirine. [35]

Three studies on MK-8195 will be presented at IAS 2019 including two late-breaker presentations on efficacy as treatment. [6, 7]

A third late-breaker abstract will present data on formulation in an annual implant for use as PrEP, extending dosing out to one year. [36]

GS-9131 - NRTI

GS-9131 is a prodrug of GS-9148 with early animal and in vitro drug resistance studies presented 12 years ago at CROI 2006. [37]

Other published studies highlight the potential for low risk of toxicity in animal studies and retains in vitro phenotypic sensitivity to broad NRTI resistance including mutations at K65R, L74V and M184V and multiple TAMS. [38]

The compound has good potency (EC50 = 25-200 nM) with activity against HIV-1 subtypes A, B, C, D, E, F, group O and N (EC50 0.29-113 nM), also against HIV-2. Synergistic activity was reported for GS-9131 in combination with AZT, FTC, abacavir, efavirenz, bictegravir, dolutegravir and lopinavir, and additive activity with TDF and TAF. [39]

Currently, the only ongoing study with GS-9131 is a phase 2 dose-finding trial in Uganda in 58 treatment-experienced women who have detectable viral load >500 copies/mL on current NRTI-including ART. GS-9131 will be added as monotherapy (using 30 mg, 60 mg and 90 mg doses) for 10 days when background ART will be changed to bictegravir plus darunavir and ritonavir, with continued GS-9131. [40]

A poster presented at CROI 2019 reported on the high in vitro threshold to drug resistance. [41]

No further results are expected at IAS 2019.

VRC01, VRC01LS and VRC07-523LS - bNAbs

VRC01 is a broadly neutralising mAb that targets the CD4 binding site that can be given by infusion or subcutaneous injection and that is in phase 1/2 development with multiple indications: for treatment, prevention and as a component of cure research.

Most ongoing studies are looking at VRC01 for HIV prevention, with two large international dose-finding, placebo-controlled phase 2 studies using VRC01 as PrEP are already ongoing that allow the option for participants to also use open-label oral TDF/FTC PrEP. [42, 43]

Although results are expected in 2019 there have always been concerns about using only a single mAb given the limited breadth and potency from one compound. Modelling suggests that nearly complete neutralisation of a given virus is needed for in vivo protection (~98% neutralisation for 50% relative protection) and that the inclusion of a second or third bNAb - is likely to be essential to provide cross-clade protection in African studies. [44]

A new long-acting formulation - VRC01LS - is also in phase 1 studies, designed to improve the half-life of the antibody, and potency from one compound. Modelling suggests that nearly complete neutralisation of a given virus is needed for in vivo protection (~98% neutralisation for 50% relative protection) and that the inclusion of a second or third bNAb - is likely to be essential to provide cross-clade protection in African studies. [44]

This includes using a single injection of VRC01LS in infants after birth to limit risk of vertical transmission and a potential role of additional injections for breastfed infants. [45]
Unfortunately, in a phase 1 study, VRC01 produced no additional impact on reducing the latently infected viral reservoir after being added to ART. VRC01 also had little impact on time to viral rebound after stopping ART, as part of a strategy in cure research.

A new long-acting formulation - VRC01LS - is also in phase 1 studies. [46, 47]

Results from the LS formulation will be presented at IAS 2019 together with VRC07-523LS – a variant long-acting bNAbs. [48]

Other bNAbs: 3BNC117 and 10-1074; PGDM1400 and PGT121; 10E8
3BNC117 and 10-1074 are two broadly neutralising mAbs that target CD4 binding that are in development at Rockefeller University.

Several phase 1 studies are using these individually and together and also in longer-acting versions that have an FcRn binding site mutation (LS) to improve pharmacokinetics. These are expected to extend the half-life by at least 4-fold, allowing monthly or two-monthly dosing.

An overview of latest results using this dual formulation was presented in one of the opening lectures to CROI 2019. [49]

This talk mainly looked at the potential for bNAbs to control HIV for extensive periods without ART, both in animal and human studies. [50, 51]

Another oral presentation at CROI 2019 included results from using a single subcutaneous injection of 10-1074 alone or in combination with 3BNC117 (10 mg each bNAb/kg) in a macaque study showed efficacy of these bNAbs as PrEP. [52]

3BNC117 is also included in a dual combination with the long-acting entry inhibitor albuvirdide that was approved last year in China. This phase 2 study with US study sites is looking at either 2-weekly or 4-weekly injection-based maintenance therapy. [53]

Also at CROI 2019, results from a phase 1 study using the bNAb PGT121 in treatment-naive participants, reported that a single infusion of PGT121 produced a median viral load reduction of −1.7 log copies/mL in participants with high baseline viral load, but breakthrough with bNAb resistance also occurred quickly when used as monotherapy. In two people starting with low baseline viral load (<400 copies/mL) a single infusion dropped viral load to undetectable where it remained, without ART, for at least eleven months. [54]

While the safety and tolerability of bNAbs are generally good, one study using the highly potent bNAb 10E8 was recently put on hold due to grade 3 skin erythema in 7/8 participants. Reactions occurred two days after receiving dual 10E8LS and VRC07 infusion (separately to each side of the stomach). These were associated with mild tenderness and fever (both transient) and confirmed by biopsy as panniculitis with lymphocytic inflammation (all cases resolved). This has been sufficient to put further clinical development of 10E8 on hold. [55]

The implications for the triple and trispecific studies that include 10E8 are unclear.

Preliminary results for a trispecific bNAb were presented at CROI 2019. This is the result of a joint development by the Vaccine Research Centre at NIAID and Sanofi where a single molecule could interact with three independent envelope regions: the CD4 binding site, MPER and the V1V2 glycan site. [56]

No further results are expected on these bNAbs at IAS 2019.

Elsulfavirine - NNRTI
Elsulfavirine (a prodrug of VM-1500A) is an NNRTI being developed by Viriom for registration in some middle-income countries.

Although limited data are available, in a randomised, double-blind phase 2b study conducted in Russia in 120 treatment naive participants, elsulfavirine 20 mg was compared to efavirenz 600 mg, each with TDF/FTC background NRTIs. The elsulfavirine arm reported similar viral suppression to <50 copies/mL (81% vs 73%), including those with baseline viral load >100,000 c/mL (78% vs 62%), with fewer CNS side effects (32% vs 62%). [57]

A long-acting injectable formulation in development, with results from an animal study presented at IAS 2017, showing the potential for monthly by intramuscular (IM) or subcutaneous (SC) injection. [58]

Phase 2 results at 96-week were presented at AIDS 2018. [59]
A second poster at IAS 2018 reported the potential for a long-acting injection formulation. [60]

However, no further results are expected at IAS 2019.

ABX464 - Rev inhibitor
ABX464 is an anti-inflammatory molecule thought to work by blocking the end stages of viral assembly. No new clinical data has been presented since 2017.

Although there are limited data as HIV treatment, results from a phase 2a dose-ranging study in 80 treatment-naive participants in Thailand reported 0.5 log copies/mL in 4/6 people at day 14 using the highest 150 mg dose as monotherapy (but with no response in 2/6). [61]

A phase 2b study looking at reducing the viral reservoir showed no change in time to viral rebound: 13 vs 14 days for days ABX464 vs placebo. [62]

An ongoing open-label phase 2 pharmacokinetic study in 36 HIV positive participants is currently ongoing, looking at 50 mg and 150 mg once-daily dosing. [63]

No further results are expected at IAS 2019.

GSK3640254 - maturation inhibitor
The maturation inhibitor GSK3640254 (previously BMS-986197) is currently in two phase 1 studies in HIV negative adults that include bioavailability of different formulations. [64, 65]

An earlier maturation inhibitor, BMS-955176, also acquired from BMS was discontinued in October 2016 due to gastrointestinal intolerability and treatment-emergent drug resistance.
Table 3: HIV pipeline compounds by development phase

<table>
<thead>
<tr>
<th>Compound/ Company</th>
<th>Class</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cabotegravir ViiV Healthcare</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cabotegravir LA rilpivirine LA ViiV Healthcare and Janssen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>fostemsavir ViiV Healthcare</td>
</tr>
<tr>
<td></td>
<td></td>
<td>lerontlimab CytoDyn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>UB-421 United BioPharma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phase 1/2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MK-8591 (EFdA) Merck/MSD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MK-8591/3TC/ doravirine Merck/MSD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GS-9131 Gilead Sciences</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VRC01 VRC01LS VRC07-523LS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3BNC117 and 10-1074; PGDM1400 and PGT121, 10E5 etc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>elsulfavirine, prodrug of VM-1500A Virion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ABX464 Abivax</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GSK3640254 ViiV Healthcare</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phase 1 and preclinical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GSP1 Gilead Sciences</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GS-CA1 Gilead Sciences</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MK-8583, MK-8527, MK-8558 Merck/MSD</td>
</tr>
</tbody>
</table>
Since the last pipeline report, results from an early phase 1 safety and tolerability study were published last year. [66]

First results from a phase 2a study in HIV positive people were presented at CROI 2019. This included mean viral load reduction of –1.5 log copies/mL in the highest dose (200 mg/day) group. [67]

No further results are expected at IAS 2019.

Preclinical compounds of interest

As many companies do not widely publicise pre-clinical work, this section is restricted to a few studies. Apart from a few new compounds, this section is largely unchanged from the 2018 pipeline report.

**Combinectin (GSK3732394) - adnectin/fusion inhibitor**

Combinectin (GSK3732394, previously BMS-986197) is a combined adnectin/fusion inhibitor that stops viral entry by targeting multiple sites of action on gp41 and CD4.

This compound has the potential for self-administered once-weekly injections.

A summary of in vitro activity and resistance data and virologic data from mouse studies were presented at Glasgow 2016. [68]

In June 2019 the first phase 1 study in HIV negative volunteers started enrolling, with results expected mid-2020. [69]

No further results are expected at IAS 2019.

**GS-PI1 - protease inhibitor**

GS-PI1 is a once-daily unboosted protease inhibitor with high potency and a long half-life, and in vitro sensitivity against some second-generation PI resistance, in pre-clinical development by Gilead.

An oral presentation at CROI 2017 reported a high barrier to resistance both after in vitro passaging and against multiple resistance complexes from multiple PI-resistant clinical isolates, and pharmacokinetic data from rat and dog studies. [70]

However, no new data have been presented since and there are no listings on the clinical trials register for new studies.

No further results are expected at IAS 2019.

**GS-CA1 - capsid inhibitor**

First phase I data was presented at CROI 2019 on GS-CA1.

This is the first HIV capsid inhibitor, with a formulation that can be used for slow-release injections. [71]

Capsid is the cone-shaped structural core within the virion that protects HIV RNA and related enzymes. As part of a dynamic process, the capsid protein (p24) first breaks down to release viral contents into the CD4 cell to enable reverse transcription and also needs to reassemble inside new virions as part of the maturation process at the end of the lifecycle.

GS-CA1 acts in both the early and late stages by binding at a site that blocks both disassembly and assembly leading to defective new virions that are non-infectious.

The compound is potent with EC50 in target cells of 60 to 140 pM (compared to 1000 to 19000 for efavirenz, dolutegravir and atazanavir) with activity against drug resistance to current HIV classes. Although population sequencing showed the binding site to be highly conserved, capsid resistance can be generated from in vitro serial passaging.

A phase I study in HIV positive participants in currently ongoing with sites in the US. [72]

No further results are expected at IAS 2019.

**MK-8583 (tenofovir prodrug), MK-8527 and MK-8558**

Three compounds being developed by Merck are currently in phase 1 studies. Although the first of these is an NRTI, the trial listings do not include the mechanism of action. [73, 74, 75]

No further results are expected at IAS 2019 for any of these compounds.
The high number of recent approvals and pending applications for new HIV drugs is impressive. (see Table 1)

It is also important that this includes new classes that will overcome drug resistance to other classes and that additional new compounds are in development, especially those that are long-acting (see Tables 3 and 4).

This investment in formulations that use less than daily dosing could dramatically change the way that HIV is treated, with several of the compounds in this report already showing the potential for monthly or perhaps annual dosing.

Other companies are also looking to invest in similar technologies, reflecting that better HIV treatments is still seen as a competitive market. [76]

The global need for better HIV treatment also means that drugs developed in high-income countries need to have data to inform their use in all settings.

Table 4: Compounds with long-acting formulations

<table>
<thead>
<tr>
<th>Compound</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>cabotegravir/rilpivirine</td>
<td>ViiV/Janssen</td>
</tr>
<tr>
<td>cabotegravir implant for PrEP</td>
<td>ViiV</td>
</tr>
<tr>
<td>MK-8591 (EIDA) yearly implant for PrEP</td>
<td>Merck/MSD</td>
</tr>
<tr>
<td>Potentially weekly or longer dosing as treatment.</td>
<td></td>
</tr>
<tr>
<td>bNAbS: 3BNC117 and 10-1074; PGD1400 and PGT121, 10E8</td>
<td>Various including Rockefeller Institute.</td>
</tr>
<tr>
<td>combinectin</td>
<td>ViiV Healthcare</td>
</tr>
<tr>
<td>elsulfavirine</td>
<td>Virion (Russia)</td>
</tr>
<tr>
<td>Gilead compounds - including CA1 capsid inhibitor.</td>
<td>Gilead Sciences (in partnership with Lyndra) - compounds not specified [74]</td>
</tr>
<tr>
<td>MK-8583, MK-8527, MK-8558</td>
<td>Merck/MSD</td>
</tr>
</tbody>
</table>

No details on compounds but likely to be long-acting.

References

Key: CROI: Conference on Retroviruses and Opportunistic Infections; IAS: International AIDS Society; HIV Glasgow: Glasgow Congress on HIV Therapy.


2. Ho D. First in human clinical evaluation of 10E8.4/iMab, a potent and broad bispecific antibody against HIV. https://www.cavid.org/grantees/Pages/Grantee-Ho4.aspx


4. Merck (MSD) press release. European Commission approves Merck’s doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®), a once-daily fixed-dose combination tablet as a complete regimen and doravirine (Fstorybook®) an NNRTI, both for the treatment of HIV-1 in appropriate patients. (30 November 2018). https://www.mrknwsroom.com

5. Merck (MSD) press release. FDA approves Merck's Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate), a once-daily fixed-dose combination tablet as a complete regimen and doravirine (Fstorybook), an NNRTI, both for the treatment of HIV-1 in appropriate patients. (30 August 2018). https://www.mrknwsroom.com

6. Molina J-M et al. MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine establishes and maintains viral suppression through 48 weeks in treatment-naive adults with HIV-1 infection. IAS 2019. Late breaker abstract WEAB0402LB. http://programme.ias2019.org/Abstract/Abstract/4789

7. Molina J-M et al. Tolerability, safety and efficacy of MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine and lamivudine through 24 weeks in treatment-naive adults with HIV-1 infection. IAS 2019. Late breaker abstract WEAB0402LB. http://programme.ias2019.org/Abstract/Abstract/4789

8. FDA announcement listserve. FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment. (8 April 2019). https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635526.htm


